Back To Schedule
Wednesday, June 21 • 10:30am - 11:45am
#312: CRISPR: Regulatory Challenges in the Gene Editing Revolution

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

This panel will explore the implications of CRISPR technology for product development and how it could bring significant changes in our treatment of disease. Panelists will discuss: the forces that will either drive the technology forward or potentially hold it up; how FDA is approaching CRISPR regulation; and global collaborative efforts to establish guiding principles for regulators.

Learning Objectives

Discuss the potential for gene editing technology to revolutionize disease management; Recall perspectives on how the technology can be used.


Nancy Bradish Myers, JD


FDA Perspective
Ritu Nalubola, PhD

Kurt von Emster, CPA

Eva Essig

avatar for Nancy Myers

Nancy Myers

CEO and Founder, Catalyst Healthcare Consulting, Inc, United States
Nancy Bradish Myers, JD, CEO & Founder, Catalyst Healthcare Consulting, is a sought-after leader with deep expertise in health law, regulation and policy. She has led a successful strategic regulatory policy consultancy for 17 years and has been active in the DC policy arena for three... Read More →

avatar for Kurt von Emster

Kurt von Emster

Managing Partner, Abingworth
Kurt joined Abingworth in 2015 and was promoted to Managing Partner shortly thereafter. He currently holds board positions at CRISPR Therapeutics, SutroVax and CymaBay. Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton in 1990... Read More →
avatar for Eva Essig

Eva Essig

Vice President, Regulatory Affairs, Intellia Therapeutics, Inc.
Eva is Vice President, Regulatory Affairs at Intellia Therapeutics. With over 25 years of experience in regulatory affairs, she has been involved in developing therapeutic biologics, small molecules, blood products and biosimilars. Most recently, she was Vice President, Global Regulatory... Read More →

Ritu Nalubola

Senior Policy Advisor, Office of Policy, Office of the Commissioner, FDA
Dr. Ritu Nalubola is a Senior Policy Advisor in FDA’s Office of Policy, Office of the Commissioner. She advises senior leadership at FDA on complex and cross-cutting policy issues, including related to biotechnology, nanotechnology, food safety, nutrition, and international consensus-based... Read More →

Wednesday June 21, 2017 10:30am - 11:45am CDT
N228 McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  02: DisruptiveInnov, Forum